Novo Nordisk A/S (NYSE:NVO) Stock Holdings Increased by Capital International Inc. CA

Capital International Inc. CA increased its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 30.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 66,448 shares of the company's stock after buying an additional 15,514 shares during the quarter. Capital International Inc. CA's holdings in Novo Nordisk A/S were worth $5,716,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in NVO. Center for Financial Planning Inc. grew its holdings in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the period. Strategic Investment Solutions Inc. IL grew its stake in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares during the period. Albion Financial Group UT increased its position in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after acquiring an additional 278 shares in the last quarter. Sound Income Strategies LLC raised its stake in shares of Novo Nordisk A/S by 82.1% in the 4th quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock valued at $46,000 after acquiring an additional 243 shares during the period. Finally, Hager Investment Management Services LLC acquired a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $46,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO traded up $1.20 during trading on Thursday, reaching $62.50. 4,495,891 shares of the company's stock traded hands, compared to its average volume of 6,056,187. The stock has a market capitalization of $280.48 billion, a P/E ratio of 19.00, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. Novo Nordisk A/S has a 12 month low of $57.00 and a 12 month high of $148.15. The company has a 50 day moving average of $74.34 and a 200-day moving average of $90.56. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were issued a $0.7874 dividend. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend was Monday, March 31st. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio (DPR) is 49.54%.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on NVO. Morgan Stanley assumed coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. Stifel Nicolaus cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Finally, BMO Capital Markets reissued a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, Novo Nordisk A/S has an average rating of "Hold" and a consensus price target of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.